利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.036 秒)

    FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES
    1.
    发明申请
    FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES 有权
    熔融的氨基二氢咪唑啉酮衍生物

    公开(公告)号：US20120202828A1

    公开(公告)日：2012-08-09

    申请号：US13386199

    申请日：2010-07-21

    申请人： Jose Luis Castro Pineiro ,  Adrian Hall ,  Andrew Madin ,  Ngoc-Tri Vo

    发明人： Jose Luis Castro Pineiro ,  Adrian Hall ,  Andrew Madin ,  Ngoc-Tri Vo

    IPC分类号： A61K31/519 ,  A61P25/28 ,  C07D491/048

    CPC分类号： C07D491/048

    摘要： A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1, R2 and Rx are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

    摘要翻译： 由通式（I）表示的化合物或其药学上可接受的盐或其溶剂合物，其中环A为C 6-14芳基等，L为-NReCO-等（其中Re为氢原子 等），环B为C 6-14芳基等，X为C 1-3亚烷基等，Y为单键等，Z为C1-3亚烷基等 R 1，R 2和R 3各自独立地为氢原子等，R 3，R 4，R 5和R 6独立地为氢原子，卤素原子等，具有A＆bgr; 产生抑制作用或BACE1抑制作用，可用作由A＆Bgr引起的神经变性疾病的预防或治疗剂; 并以阿尔茨海默氏型痴呆为代表。

    Fused aminodihydropyrimidone derivatives
    2.
    发明授权
    Fused aminodihydropyrimidone derivatives 有权
    熔融氨基二氢嘧啶酮衍生物

    公开(公告)号：US09139594B2

    公开(公告)日：2015-09-22

    申请号：US13386199

    申请日：2010-07-21

    申请人： Jose Luis Castro Pineiro ,  Adrian Hall ,  Andrew Madin ,  Ngoc-Tri Vo

    发明人： Jose Luis Castro Pineiro ,  Adrian Hall ,  Andrew Madin ,  Ngoc-Tri Vo

    IPC分类号： A61K31/519 ,  A61P25/28 ,  C07D491/048

    CPC分类号： C07D491/048

    摘要： A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1, R2 and Rx are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

    摘要翻译： 由通式（I）表示的化合物或其药学上可接受的盐或其溶剂合物，其中环A为C 6-14芳基等，L为-NReCO-等（其中Re为氢原子 等），环B为C 6-14芳基等，X为C 1-3亚烷基等，Y为单键等，Z为C1-3亚烷基等 R 1，R 2和R 3各自独立地为氢原子等，R 3，R 4，R 5和R 6独立地为氢原子，卤素原子等，具有A＆bgr; 产生抑制作用或BACE1抑制作用，可用作由A＆Bgr引起的神经变性疾病的预防或治疗剂; 并以阿尔茨海默氏型痴呆为代表。

    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists
    8.
    发明授权
    Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists 失效
    氮杂环丁烷，吡咯烷和哌啶衍生物作为5-HT受体激动剂

    公开(公告)号：US6140347A

    公开(公告)日：2000-10-31

    申请号：US171208

    申请日：1998-10-14

    申请人： Jose Luis Castro Pineiro ,  Andrew Madin ,  Joseph George Neduvelil ,  Graham Andrew Showell ,  Leslie Joseph Street ,  Monique Bodil Van Niel

    发明人： Jose Luis Castro Pineiro ,  Andrew Madin ,  Joseph George Neduvelil ,  Graham Andrew Showell ,  Leslie Joseph Street ,  Monique Bodil Van Niel

    IPC分类号： C07D521/00 ,  A61K31/445 ,  A61K31/415 ,  C07D401/14

    CPC分类号： C07D231/12 ,  C07D233/56 ,  C07D249/08

    摘要： A class of compounds of formula (I) wherein Z, E, Q, T, U, V, W, M, R.sup.1, R.sup.7 and R.sup.8 are as defined herein; are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##

    摘要翻译： PCT No.PCT / GB97 / 01137 Sec。 371日期：1998年10月14日 102（e）日期1998年10月14日PCT 1997年4月24日PCT公布。 出版物WO97 / 42189 日期：1997年11月13日一类其中Z，E，Q，T，U，V，W，M，R 1，R 7和R 8如本文所定义的式（I）化合物; 是5-HT1样受体的选择性激动剂，其是人类5-HT1Dα受体亚型的有效激动剂，同时相对于5-HT1Dβ亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此，它们可用于治疗和/或预防临床状况，特别是偏头痛和相关疾病，其中指出5-HT1D受体的亚型选择性激动剂，同时引起较少的副作用，特别是不利的心血管事件，比 与非亚型选择性5-HT1D受体激动剂相关的那些。